MX2021003450A - Metodos para tratar trastornos mieloproliferativos. - Google Patents

Metodos para tratar trastornos mieloproliferativos.

Info

Publication number
MX2021003450A
MX2021003450A MX2021003450A MX2021003450A MX2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A
Authority
MX
Mexico
Prior art keywords
methods
myeloproliferative disorders
treating myeloproliferative
treating
disorders
Prior art date
Application number
MX2021003450A
Other languages
English (en)
Inventor
John Hood
Tymara Berry
Catriona Jamieson
Curtis L Scribner
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69950867&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021003450(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of MX2021003450A publication Critical patent/MX2021003450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente descripción proporciona métodos para mitigar la deficiencia de tiamina.
MX2021003450A 2018-09-25 2019-09-24 Metodos para tratar trastornos mieloproliferativos. MX2021003450A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US201862783076P 2018-12-20 2018-12-20
PCT/US2019/052608 WO2020068755A1 (en) 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
MX2021003450A true MX2021003450A (es) 2021-07-16

Family

ID=69950867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003450A MX2021003450A (es) 2018-09-25 2019-09-24 Metodos para tratar trastornos mieloproliferativos.

Country Status (13)

Country Link
US (2) US20220031699A1 (es)
EP (1) EP3856169A4 (es)
JP (1) JP2022502492A (es)
KR (1) KR20210102192A (es)
CN (1) CN113286584A (es)
AU (1) AU2019346521A1 (es)
BR (1) BR112021005518A2 (es)
CL (1) CL2021000744A1 (es)
IL (1) IL281736A (es)
MA (1) MA53741A (es)
MX (1) MX2021003450A (es)
SG (1) SG11202103019WA (es)
WO (1) WO2020068755A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019349652A1 (en) * 2018-09-25 2021-05-13 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
AU2019346521A1 (en) 2018-09-25 2021-05-20 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
WO2022132933A1 (en) 2020-12-16 2022-06-23 Impact Biomedicines, Inc. Dosing of fedratinib
EP4297750A1 (en) 2021-02-25 2024-01-03 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
WO2023044297A1 (en) 2021-09-14 2023-03-23 Impact Biomedicines, Inc. Fedratinib for treating myeloproliferative disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
AU2014354769A1 (en) 2013-11-26 2016-05-26 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CA2936865A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3331550B1 (en) * 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
AU2019349652A1 (en) 2018-09-25 2021-05-13 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
AU2019346521A1 (en) 2018-09-25 2021-05-20 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
CN113840604A (zh) 2019-02-12 2021-12-24 生物医学影响公司 Jak2抑制剂的结晶形式
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2

Also Published As

Publication number Publication date
BR112021005518A2 (pt) 2021-06-29
WO2020068755A1 (en) 2020-04-02
MA53741A (fr) 2021-08-04
EP3856169A4 (en) 2022-06-29
JP2022502492A (ja) 2022-01-11
AU2019346521A1 (en) 2021-05-20
IL281736A (en) 2021-05-31
SG11202103019WA (en) 2021-04-29
CN113286584A (zh) 2021-08-20
EP3856169A1 (en) 2021-08-04
US20220031699A1 (en) 2022-02-03
KR20210102192A (ko) 2021-08-19
US11400092B2 (en) 2022-08-02
US20220133724A1 (en) 2022-05-05
CL2021000744A1 (es) 2021-10-08

Similar Documents

Publication Publication Date Title
MX2021003450A (es) Metodos para tratar trastornos mieloproliferativos.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
MX2021006439A (es) Reguladores del cftr y metodos para su uso.
EP3852700A4 (en) SYSTEMS AND METHODS OF TREATMENT OF CORNEAL ECTASIA
PH12019500479A1 (en) Compositions for treating dementia
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
MX2021014484A (es) Moduladores de la progranulina y metodos de uso de estos.
JOP20210107A1 (ar) مضمنات التعبير عن foxp3
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors